Nivolumab–ipilimumab receives nod from EMA for malignant pleural mesothelioma
medwireNews: The EMA has adopted a positive opinion for the use of nivolumab in combination with ipilimumab for the first-line treatment of adult patients with inoperable malignant pleural mesothelioma.
The decision from the EMA’s Committee for Medicinal Products for Human Use follows on from results of the phase 3 CheckMate 743 trial, which showed a significant overall survival benefit with the immunotherapy duo versus platinum-doublet chemotherapy in this patient population.
The combination was approved for this indication by the US FDA in October 2020, and it is also authorized for use in both the USA and Europe to treat non-small-cell lung cancer.
medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group